Health Condition 1: O- Medical and Surgical
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients aged 20 35 years (both males and females) who consented to participate 2)Systemically healthy individuals Diagnosed with Stage II and Stage III periodontitis (Excluding teeth with furcation involvement and mobility) 3)Presence of vertical bone loss of 3 4 mm on radiographic examination 4)Two-wall or three-wall intrabony defects with: Defect depth more 3 mm (confirmed radiographically and intraoperatively) 5)Clinical attachment loss (CAL): 3 6 mm 6)Patients available for regular follow-up visits 7)Patients who provided signed informed consent
Exclusion criteria
Exclusion criteria: 1)Smokers 2)Known allergy or hypersensitivity to Tetracycline groups 3)Patients with uncontrolled systemic diseases (e.g., diabetes, hypertension) that could affect periodontal treatment outcomes. 4)Patients with blood-borne diseases (e.g., HIV, hepatitis). 5)Medications Affecting Blood Clotting:- Patients taking medications that could affect blood clotting (e.g., anticoagulants, antiplatelet agents). 6)Patients with previous history of undergoing flap surgery 7)Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the radiographic bone fill in intrabony defects treated with tetracycline-loaded biodegradable fibers with PRF and PRF alone, measured by standardized radiovisiography (Fractal Dimensional Analysis) over a defined follow up period of baseline, 1 month, 3 monthTimepoint: To compare the radiographic bone fill in intrabony defects treated with tetracycline-loaded biodegradable fibers with PRF and PRF alone, measured by standardized radiovisiography (Fractal Dimensional Analysis) over a defined follow up period of baseline, 1 month, 3 month | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the radiographic bone fill in intrabony defects treated with tetracycline-loaded biodegradable fibers with PRF and PRF alone, measured by standardized radiovisiography (Fractal Dimensional Analysis) over a defined follow up periodTimepoint: baseline, 1 month, 3 months; To assess the reduction in probing pocket depth (PPD) in intrabony defects treated with tetracycline-loaded biodegradable fibers with PRF and PRF alone over a follow up period of baseline, 1 month, 3 months. To evaluate the gain in clinical attachment level (CAL) following treatment with both modalities over a follow up period of baseline, 1month, 3 months. To compare changes in Plaque Index (PI) after therapy among both groups over a follow up period of baseline, 1month, 3 months. To compare changes in Gingival Index (GI) after therapy among both groups over a period of baseline, 1 month, 3 months. To compare changes in the Healing Index after therapy among both groups over a period of baseline & 3 months. To evaluate Complete blood count in experimental groups in baseline and 3 months. Timepoint: baseline, 1 months, 3 months | — |
Countries
India
Contacts
Sri Venkateshwaraa Dental College